Efficacy and Safety Study of Zinc Acetate to Treat Wilson's Disease in Japan.

This study is ongoing, but not recruiting participants.

First Received: September 13, 2005 No Changes Posted

Sponsored by:	Nobelpharma
Information provided by:	Nobelpharma
ClinicalTrials.gov Identifier:	NCT00212368

Purpose

The purpose of this study is to determine whether Zinc Acetate is effective and safe in the treatment of Wilson's disease among Japanese.

Condition	Intervention	Phase
Wison's Disease	Drug: Zinc acetate	Phase III

Genetics Home Reference related topics: familial paroxysmal nonkinesigenic dyskinesia succinic semialdehyde dehydrogenase deficiency Wilson disease

MedlinePlus related topics: Wilson Disease

Drug Information available for: Zinc acetate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Phase3,Open-Label,Clinical Trial of Zinc Acetate for Treatment of Wilson's Disease in Japan.

Eligibility

Ages Eligible for Study:	1 Year and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Wilson's disease(adult,infant,pregnant woman)

Exclusion Criteria:

acute hepatitis
malignant tumor

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00212368

Sponsors and Collaborators

Nobelpharma

Investigators

Study Director:

Koudou Ishii, M.D.

National MINAMIYOKOHAMA Hospital

More Information

No publications provided

Study ID Numbers:	NPC-02-1
Study First Received:	September 13, 2005
Last Updated:	September 13, 2005
ClinicalTrials.gov Identifier:	NCT00212368 History of Changes
Health Authority:	Japan: Pharmaceuticals and Medical Devices Agency

Study placed in the following topic categories:

Liver Diseases
Metabolic Diseases
Ganglion Cysts
Hepatolenticular Degeneration
Basal Ganglia Diseases
Central Nervous System Diseases
Brain Diseases
Neurodegenerative Diseases
Metabolism, Inborn Errors

Digestive System Diseases
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn
Wilson Disease
Movement Disorders
Zinc
Brain Diseases, Metabolic, Inborn
Metabolic Disorder
Brain Diseases, Metabolic

Additional relevant MeSH terms:

Liver Diseases
Metabolic Diseases
Hepatolenticular Degeneration
Basal Ganglia Diseases
Nervous System Diseases
Central Nervous System Diseases
Brain Diseases
Neurodegenerative Diseases

Metal Metabolism, Inborn Errors
Metabolism, Inborn Errors
Digestive System Diseases
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn
Movement Disorders
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic

ClinicalTrials.gov processed this record on May 07, 2009